OwlTail

Cover image of 2015 ASCO Annual Meeting

2015 ASCO Annual Meeting

2015 ASCO Annual Meeting

Weekly hand curated podcast episodes for learning

Popular episodes

All episodes

Warning: This podcast data isn't working.

This means that the episode rankings aren't working properly. Please revisit us at a later time to get the best episodes of this podcast!

Podcast cover

Lenvatinib increases progression free survival when used with everolimus in metastatic renal cell carcinoma

Dr Larkin talks to ecancertv at ASCO 2015 about the results of a randomised phase II trial of kinase inhibitor lenvatinib used in combination with everolimus in renal cell carcinoma, which saw significant improvements in progression free survival compared with everolimus alone.

4mins

8 Aug 2017

Rank #1

Podcast cover

Cobimetinib plus vemurafenib for advanced BRAF-mutated melanoma

Dr Larkin talks to ecancertv at ASCO 2015 about an update on a phase III study of cobimetinib plus vemurafenib in advanced BRAF-mutated melanoma: Progression-free survival and correlative biomarker analysis from the coBRIM trial.Longer follow-up has confirmed the clinical benefit of vemurafenib and cobimetinib in patients with advanced BRAF V600-mutated melanoma.Co-existence of BRAF V600 and baseline activating RAS/RAF/RTK mutations do not seem to affect disease progression or rate of response to the treatment.

3mins

8 Aug 2017

Rank #2

Podcast cover

Enzalutamide preferable to bicalutamide plus LHRH analogue in prostate cancer

Dr Chowdhury talks to ecancertv at ASCO 2015 about the results of the TERRAIN study which looked at the use of 160 mg of enzalutamide taken orally once daily versus bicalutamide at a dose of 50mg taken once daily in combination with an LHRH analogue in patients with metastatic prostate cancer whose disease had progressed despite treatment with luteinizing hormone-releasing hormone (LHRH) analogue therapy or surgical castration.Results showed median progression free survival was 15.7 months in the enzalutamide arm compared to 5.8 months in the bicalutamide plus LHRH analogue arm (HR 0.44, 95% CI 0.34-0.57; p<0.0001).He also comments on the STAMPEDE trial, which found that adding docetaxel chemotherapy to standard hormone therapy markedly improved survival for men with newly diagnosed advanced prostate cancer not previously treated with hormone therapy (hormone- naïve).

7mins

8 Aug 2017

Rank #3

Podcast cover

Medically under-represented populations: Refining the calculation of accrual targets

Dr Comis talks to ecancertv at ASCO 2015 about a National Cancer Institute (NCI) sponsored cancer clinical trial for under-represented populations that aims to refine the calculation of accrual targets.

4mins

8 Aug 2017

Rank #4

Most Popular Podcasts

Podcast cover

Adjuvant denosumab may preserve bone health in postmenopausal breast cancer patients: results of the ABCSG-18 trial

Prof Gnant talks to ecancertv at ASCO 2015 about the use of adjuvant denosumab to reduce bone problems in postmenopausal women with breast cancer receiving treatment with aromatase inhibitors.Adjuvant endocrine therapy compromises bone health in patients with breast cancer, causing osteopaenia, osteoporosis, and fractures - but the addition of adjuvant denosumab to the treatment plan reduces patients' risk of clinical fractures.

5mins

8 Aug 2017

Rank #5

Podcast cover

ASCO 2015: Latest developments in multiple myeloma

Prof Moreau (Centre Hospitalier Universitaire de Nantes, Nantes, France) chairs a discussion for ecancertv with Prof Lonial (Emory University, Atlanta, USA) and Prof Dimopoulos (University of Athens, Athens, Greece) about the latest in multiple myeloma, including data presented at ASCO 2015.They discuss the latest in protease inhibitors and immunotherapy with particular reference to carfilzomib, bortezomib, and elotuzumab.

10mins

8 Aug 2017

Rank #6

Podcast cover

Initial nivolumab-based treatment halts melanoma progression

Dr Wolchok talks to ecancertv at ASCO 2015 about results from a randomised phase III trial which indicate that initial therapy with nivolumab alone or in combination with ipilimumab is significantly more effective than ipilimumab alone.These results represent yet another major step forward in tackling melanoma.

6mins

8 Aug 2017

Rank #7

Podcast cover

Round-up of the latest research on lung cancer

Dr Spicer talks to ecancertv at ASCO 2015, about the progress of recent drug development in lung cancer treatments.

9mins

8 Aug 2017

Rank #8

Podcast cover

Preliminary analysis on the RNA sequencing data of lung squamous cell carcinoma

Prof Wu talks to ecancertv at ASCO 2015 about EGFR inhibition in lung cancer.

4mins

8 Aug 2017

Rank #9

Podcast cover

Advanced DNA sequencing test used to match rare cancers

Dr Doroshow (National Cancer Institute, Bethesda, USA), Dr Flaherty (Massachusetts General Hospital, Boston, USA) and Dr Conley (Division of Cancer Treatment & Diagnosis, NCI , USA) present, at a press conference at ASCO 2015, about the trial: NCI-Molecular Analysis for Therapy Choice (NCI-MATCH)A clinical trial that will analyse patients’ tumours to determine whether they contain genetic abnormalities for which a targeted drug exists (that is, “actionable mutations”) and assign treatment based on the abnormality.

16mins

8 Aug 2017

Rank #10